Search

Displaying results 6451 - 6460 of 7604 in total
  1. Drug

    Sabestomig

    go.drugbank.com/drugs/DB19326
    Investigational

    Sabestomig is under investigation in clinical trial NCT05216835 (Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma).

  2. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form

  3. Drug

    Lurtotecan

    go.drugbank.com/drugs/DB12222
    Investigational

    Lurtotecan is under investigation in clinical trial NCT00022594 (Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer).

  4. Drug

    Nolatrexed

    go.drugbank.com/drugs/DB12912
    Experimental

    Nolatrexed is under investigation in clinical trial NCT00012324 (Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer).

  5. Drug

    Recombinant CD40-ligand

    go.drugbank.com/drugs/DB15015
    Investigational

    Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).

  6. Drug

    Etigilimab

    go.drugbank.com/drugs/DB18854
    Investigational

    Etigilimab is under investigation in clinical trial NCT04761198 (A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.).

  7. Drug

    ARX517

    go.drugbank.com/drugs/DB23076
    Investigational

    ARX517 is under investigation in clinical trial NCT04662580 (ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer).

  8. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.

  9. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    [L43567] The FDA has granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of patients with Canavan disease.[L43572]

  10. Drug

    Enadenotucirev

    go.drugbank.com/drugs/DB14873
    Investigational

    Enadenotucirev is under investigation in clinical trial NCT02636036 (Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors).